目的：评价新一代抗组胺药物氯雷他定治疗儿童哮喘的疗效和安全性，为儿童哮喘的治疗提供临床依据。方法：采用计算机及手工检索方式检索PubMed、MEDLINE、EMBASE、Cochrance、CNKI、CBMdisc等数据库（1990年1月至2010年12月）。对文献质量进行内部真实性评价，并按Cochrane协作网推荐的方法进行系统评价和分析。结果：检索到文献179篇，最终纳入11篇随机对照研究，共有317例哮喘儿童，其中氯雷他定治疗组159例，安慰剂治疗组（对照组）158例。所有纳入文献质量为B级。Meta分析的结果表明，治疗后氯雷他定组的临床评分、4周和8周的一秒用力呼气容积（FEV1）、8周的呼吸流速峰值（PEFR）均明显优于对照组（P<0.01），差异均有统计学意义。而氯雷他定组乏力和心动过速及心悸的发生比率均低于对照组，差异有统计学意义。结论：采用氯雷他定治疗儿童哮喘安全有效，值得在临床进行推广。
Abstract
OBJECTIVE: To evaluate the efficacy and safety of loratadine, a new generation of antihistaminics, in the treatment of childhood asthma. METHODS: The papers related to loratadine treatment for childhood asthma were searched in the database of PubMed, MEDLINE, EMBASE, Cochrance, CNKI and CBMdisc (January 1990 to December 2010) electronically and manually. According to the Cochrane reviewer’s handbook, the quality of the enrolled papers was assessed and a systematic review was performed. RESULTS: A total of 179 papers were obtained. Eleven randomized controlled trials met the criteria and were included in this study. The 11 trials included 317 children with asthma: 159 cases in the loratadine treatment group and 158 cases in the control group. All included studies belonged to the B class according to the quality evaluation criteria. Meta analysis showed that the clinical symptoms were improved more, the forced expiratory volume in 1 second (FEV1) 4 and 8 weeks posttreatment and the peak expiratory flow rate (PEFR) 8 weeks posttreatment were higher in the loratadine treatment group than in the control group. The treatment-related adverse effects, fatigue, tachycardia and palpitation, occurred less in the loratadine treatment group compared with the control group. CONCLUSIONS: Loratadine is safe and effective for the treatment of childhood asthma.
关键词
氯雷他定 /
疗效 /
安全性 /
Meta分析 /
儿童
Key words
Loratadine /
Efficacy /
Safety /
Meta analysis /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］Boquete M, Carballada F.Childhood asthma and viral infection: interactions and therapeutic possibilities［J］. Allergol Immunopathol (Madr), 2001, 29(3): 133-140.
［2］Hallstrand TS, Moody MW, Wurfel MM, Schwartz LB, Henderson WR Jr, Aitken ML. Inflammatory basis of exercise-induced bronchoconstriction［J］.Am J Respir Crit Care Med, 2005, 172(6): 679-686.
［3］Davis BE, Illamperuma C, Gauvreau GM, Watson RM, O′Byrne PM, Deschesnes F, et al. Single-dose desloratadine and montelukast and allergen-induced late airway responses［J］. Eur Respir J, 2009, 33(6): 1302-1308.
［4］Jackson DJ. The role of rhinovirus infections in the development of early childhood asthma［J］. Curr Opin Allergy Clin Immunol, 2010, 10(2)：133-138.
［5］Gern JE. The urban environment and childhood asthma study［J］. J Allergy Clin Immunol, 2010, 125(3): 545-549.
［6］Li J, Luo DF, Li SY, Sun BQ, Zhong NS. Efficacy of intramuscular BCG polysaccharide nucleotide on mild to moderate bronchial asthma accompanied with allergic rhinitis: a randomized, double blind, placebo-controlled study［J］.Chin Med J (Engl), 2005, 118(19): 1595-1603.
［7］Lakomski PG, Chitre M. Evaluation of the utilization patterns of leukotriene modifiers in a large managed care health plan［J］.J Manag Care Pharm, 2004, 10(2): 115-121.
［8］Lee DK, Haggart K, Currie GP, Anderson SD, Lipworth BJ. The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis［J］. Br J Clin Pharmacol, 2003, 55(6): 639-642.
［9］Baki A, Orhan F. The effect of loratadine in exercise-induced asthma［J］. Arch Dis Child, 2002, 86(1): 38-39.
［10］Peroni DG, Piacentini GL, Pietrobelli A, Loiacono A, De Gasperi W, Sabbion A, et al. The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children［J］. Eur Respir J, 2002, 20(1): 104-107.
［11］Yang YH, Lin YT, Lu MY, Tsai MJ, Chiang BL. A double-blind, placebo-controlled, and randomized study of loratadine (Clarityne) syrup for the treatment of allergic rhinitis in children aged 3 to 12 years［J］. Asian Pac J Allergy Immunol, 2001, 19(3): 171-175.
［12］Nash DB, Sullivan SD, Mackowiak J. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting［J］. Am J Manag Care, 2000, 6(1 Suppl): S3-S15.
［13］Reicin A, White R, Weinstein SF, Finn AF Jr, Nguyen H, Peszek I, et al. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma［J］. Arch Intern Med, 2000, 160(16): 2481-2488.
［14］Roquet A, Dahlen B, Kumlin M, Ihre E, Anstren G, Binks S, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics［J］. Am J Respir Crit Care Med, 1997, 155(6): 1856-1863.
［15］Liao E, Leahy M, Cummins G. The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis［J］. Am J Manag Care, 2001, 7(15 Suppl): S459-S468.
［16］赵京. 变应原特异性免疫治疗［J］.实用儿科临床杂志，2008，23(9)： 646-648.
PDF(1248 KB)
